Media headlines about Allergan (NYSE:AGN) have trended extremely negative on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than 6,000 blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allergan earned a news sentiment score of -4.00 on their scale. InfoTrie also gave headlines about the company an news buzz score of 6 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have impacted Allergan’s analysis:
- Axillary Hyperhidrosis Treatment Market 2020 Trending With Major Eminent Key Players | Allergan Inc. Miramar Labs Inc., GlaxoSmithKline Plc. and Ulthera Inc. – Associated Press (apnews.com)
- Imagine Receives Grant from The Allergan Foundation (tapinto.net)
- Pre-tax profits at Botox maker Allergan Ireland decline by 17pc to $187m (independent.ie)
- Allergan Says State Laws Doom Restasis Payors’ Class Push (law360.com)
- Facial Injectables Market – Global Forecast to 2025: Key Vendors are Allergan, Galderma, Merz Pharma, Ipsen – ResearchAndMarkets.com – Business Wire (businesswire.com)
Shares of AGN opened at $186.37 on Friday. Allergan has a 12-month low of $114.27 and a 12-month high of $186.91. The business’s fifty day moving average is $180.39 and its 200 day moving average is $161.42. The company has a quick ratio of 0.88, a current ratio of 1.00 and a debt-to-equity ratio of 0.33. The stock has a market cap of $61.18 billion, a P/E ratio of 11.17, a P/E/G ratio of 2.18 and a beta of 1.64.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $4.25 EPS for the quarter, meeting the Zacks’ consensus estimate of $4.25. The business had revenue of $4.03 billion during the quarter, compared to analyst estimates of $3.88 billion. Allergan had a negative net margin of 58.50% and a positive return on equity of 9.08%. Allergan’s quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.25 EPS. On average, analysts expect that Allergan will post 16.89 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.59%. The ex-dividend date is Tuesday, November 12th. Allergan’s dividend payout ratio is currently 17.74%.
AGN has been the subject of several recent analyst reports. Wells Fargo & Co reaffirmed an “outperform” rating and set a $184.00 price objective (up previously from $176.00) on shares of Allergan in a research report on Monday, September 30th. UBS Group downgraded shares of Allergan from a “buy” rating to a “neutral” rating and boosted their target price for the company from $189.00 to $203.00 in a research report on Tuesday, November 19th. Finally, ValuEngine downgraded shares of Allergan from a “hold” rating to a “sell” rating in a research report on Wednesday, October 30th. Two investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and four have assigned a buy rating to the stock. Allergan presently has a consensus rating of “Hold” and a consensus target price of $175.90.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Read More: G-20
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.